The BTA stat test: A tumor marker for the detection of upper tract transitional cell carcinoma

Urology

Volumn 58, Issue 4, 2001, Pages 532-535

  Walsh, Ian K ^a   Keane, Patrick F ^a   Ishak, Laura M ^b   Flessland, Karen A ^c  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b Private Practice   (United States)

^c Bion Diagnostic Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST; FEMALE; HEMATURIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT CARCINOMA; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS;

EID: 0034800851     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01307-3     Document Type: Article

References (18)

1. Upper tract recurrences following radical cystectomy; an analysis of prognostic factors, recurrence patterns, and stage at presentation
2. Upper tract tumours following cystectomy for bladder cancer; is routine intravenous urography worthwhile?
3. Should the follow-up of patients with bladder cancer include routine excretory urography?
4. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter
5. Urinary cytology and the clinical diagnosis of urinary tract malignancy; a clinicopathological study of 1400 patients
6. Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer
7. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder
8. Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis
9. Improved detection of recurrent bladder cancer using the Bard BTA stat test
10. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer
11. Noninvasive detection of bladder cancer with the BTA stat test
12. Comparison of screening methods in the detection of bladder cancer
13. Specificity of human complement factor H-related protein test (Bard BTA stat Test)
14. Urinary beta-glucuronidase activity as an initial screening test for urinary tract malignancy in high risk patients
15. Primary grade I transitional cell carcinoma of the renal pelvis and ureter
16. Human complement factor H related protein test for monitoring bladder cancer
17. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis